Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2025
0mins
Source: Business Insider
Analyst Rating: Canaccord Genuity's Elyse Shapiro maintains a Buy rating on Immutep Ltd with a price target of A$0.95, while the company has a Moderate Buy consensus among analysts.
Performance Metrics: Shapiro has an average return of -13.6% and a success rate of 30.89% on her stock recommendations; Immutep Ltd's stock has fluctuated between $0.16 and $0.38 over the past year.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMP is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.940
Low
12.00
Averages
12.00
High
12.00
Current: 2.940
Low
12.00
Averages
12.00
High
12.00
No data
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
